FONR
FONAR Corporation
NASDAQ · Healthcare · Medical - Devices · US
$19.09
+0.00%Year over year
Reported trailing growth
- Revenue
- +2.3%
- EBITDA
- -7.0%
- EBIT
- -20.8%
- EPS
- -20.5%
- Free cash flow
- -45.3%
- Operating cash flow
- -35.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2.3%
- EBITDA
- -12.5%
- EBIT
- -19.2%
- Net income
- -12.5%
- EPS
- -10.9%
- Free cash flow
- -11.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026